Sionna Therapeutics is a clinical-stage biopharmaceutical company focused exclusively on cystic fibrosis. It develops small-molecule medicines designed to stabilize CFTR’s nucleotide-binding domain 1 (NBD1), aiming to correct defects linked to the common F508del mutation and more fully restore CFTR function. Its pipeline of NBD1 stabilizers and complementary CFTR modulators targets people with CF who may still have unmet need despite existing modulator therapies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -18.1 | — |
| Q3 2025 | 0 | — | -20.3 | — |
| Q4 2025 | 0 | — | -20.4 | — |
| Q1 2026 | 0 | — | -26.8 | — |
| Q2 2026 | 0 | — | -29.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: ioneer Ltd (IONR), Irenic Acquisition Corp. (IACQU), Imperial Petroleum Inc. (IMPP), Meridian Corporation (MRBK), Entrada Therapeutics, Inc. (TRDA), Expensify, Inc. (EXFY)